The charts below show the distribution of prescribing behaviour across CCGs in NHS England on various measures covering safety, efficacy and cost-effectiveness (read more about these).
If all CCGs across England had prescribed at least as well
as the median CCG on the cost-saving measures the monthly
cost saving in February 2021 would have
If they had prescribed as well as the best decile the saving would have been:
NHS England produce a list of products considered low priority for funding by the NHS. The total monthly spend on such products in February 2021 was: £6,282,000
If every CCG had prescribed low priority products at least
as sparingly as the median CCG the monthly cost saving in
February 2021 would have been:
If they had prescribed at the level achieved by the best decile the saving
would have been:
There is wide variation in the unit cost of a number of medicines prescribed across England, due to the way the reimbursement system is structured.
We have calculated the potential monthly cost saving if every CCG
achieved the unit cost obtained by the best 10%.
In February 2021 this was:
We have estimated the additional spending due to price concessions on
out-of-stock products by taking the latest available prescribing data from
and projecting forwards.
In April 2021 this amounts to:
These measures support work to reduce the impact of medicines on overall enviromental impact of the NHS.